HER2 Biomarker Detection for Breast Cancer Therapy Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods lack sensitivity and specificity in monitoring breast cancer progression and responding to therapies, particularly in breast cancer patients where HER2 status can change from HER2-negative to HER2-positive, leading to resistance or de novo resistance to ErbB-targeted therapies.
Innovation Solution
A method involving contacting breast cancer cells with a compound that modulates HER2 activity, lysing the cells to produce a cellular extract, and determining the activation level of HER2 and p95HER2, comparing these levels to reference activation levels from sensitive or resistant cells to predict sensitivity or resistance, aiding in selecting appropriate therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current cancer treatment methods are used to monitor breast cancer progression and response to therapies, then treatment can be administered, but sensitivity and specificity in monitoring are insufficient, leading to inability to detect HER2 status changes
Solution Approach 1:
The patent segments the monitoring process into multiple distinct steps: (1) obtaining a biological sample from the patient, (2) extracting RNA from the sample, (3) analyzing expression levels of multiple specific genes (HER2, p95HER2, and other biomarkers), and (4) comparing results to reference values. This segmentation allows for precise measurement of individual gene expression levels while maintaining overall reliability in detecting HER2 status changes.
Solution Approach 2:
The patent uses RNA expression levels as an intermediary marker to detect HER2 status changes. Instead of directly measuring HER2 protein or tumor characteristics, the method measures mRNA expression levels of HER2, p95HER2, and other genes, which serve as intermediaries that reflect the functional state of HER2 signaling pathways and predict response to targeted therapies.
2Productivity
If HER2 status is not accurately monitored, then treatment decisions can be made without frequent testing, but therapy selection becomes inappropriate, leading to resistance or de novo resistance to ErbB-targeted therapies
Solution Approach 1:
The patent performs preliminary analysis of multiple gene expression levels (HER2, p95HER2, and other biomarkers) before making treatment decisions. By obtaining baseline RNA expression data and comparing it to reference values, the method enables proactive identification of HER2-positive status and appropriate therapy selection before resistance develops, rather than waiting for treatment failure.
Solution Approach 2:
The patent establishes a feedback mechanism where RNA expression levels are measured, compared to reference values, and used to guide treatment selection and monitoring. This feedback loop allows clinicians to adjust therapy based on actual molecular profile changes, ensuring adaptability when HER2 status changes from negative to positive or vice versa during the course of treatment.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides compositions and methods for detecting the expression and/or activation states of components of signal transduction pathways in cells such as tumor cells. Information on the expression and/or activation states of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.